Johnson & Johnson (JNJ) has proposed a $5.5 billion settlement to resolve approximately 76,000 ovarian cancer lawsuits filed at both the multi-district litigation and state levels.
Law firms representing 99.75% of plaintiffs have signed off on the proposal, marking a significant step toward closing one of the most prolonged product liability disputes in US corporate history.
The deal would take effect if accepted by at least 95% of plaintiffs, which J&J says would effectively end its talc litigation in the United States after more than a decade of legal battles.
J&J shares rose roughly 2% following the announcement, and the company’s stock has climbed 31% since the beginning of the year, reflecting growing investor confidence in the resolution.
The proposed settlement follows a Los Angeles jury ruling in early June that sided with J&J in a multi-district litigation case involving three deceased women, finding the company was not negligent in selling cosmetic talc products.
A federal judge also recently ordered plaintiffs to show why remaining talc claims should not be dismissed after their witnesses failed to establish a direct link between J&J’s products and cancer.
“The Court’s order placed plaintiffs in an untenable position of having to present specific causation evidence to maintain their claims that does not exist,” said Erik Haas, worldwide vice president of litigation at Johnson & Johnson.
Christopher Seeger, the plaintiffs’ lead negotiation counsel in the MDL, acknowledged the human cost of the lengthy legal process, saying: “More than a decade of protracted litigation and three failed bankruptcies has left tens of thousands of women and their families waiting far too long for relief.”
The settlement does not place a cap on J&J’s total payout, and attorney Chris Seeger noted the company could ultimately pay $7 billion or more depending on the volume of qualifying claims.
J&J has confirmed it will pay $3 billion of the settlement amount in 2027, with the full resolution expected to take a number of months to complete following plaintiff acceptance.
Throughout the litigation, J&J has maintained that no conclusive evidence exists linking its talc products to asbestos contamination or cancer, and the company stopped selling talc-based baby powder in the US and Canada in 2020.
Erik Haas said the claims “lack scientific merit” but added that settling offers the company a path forward, stating J&J remains “confident the Company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date.”
Notably, the settlement does not extend to the United Kingdom, where the largest product liability case in UK legal history is currently being adjudicated, covering more than 7,000 potential claimants.
That UK case, filed in October 2025, alleges J&J knowingly continued to sell talc products despite being aware they could cause ovarian cancer and mesothelioma, a claim the company firmly denies.